Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A peptide consisting of the amino acid sequence of SLLELDGINL (SEQ ID NO: 72) in the form of pharmaceutically acceptable salt.
2. The peptide according to claim 1 , wherein said peptide has the ability to bind to an MHC class-I or II molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and/or CD8 T cells.
3. The peptide according to claim 1 , wherein said peptide is bound in an MHC complex.
4. A pharmaceutical composition comprising the peptide of claim 1 and an immune-stimulating adjuvant.
5. The pharmaceutical composition of claim 4 , wherein the immune-stimulating adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
6. The pharmaceutical composition of claim 5 , wherein the immune-stimulating adjuvant is IL-2.
7. The pharmaceutical composition of claim 5 , wherein the immune-stimulating adjuvant is IL-7.
8. The pharmaceutical composition of claim 5 , wherein the immune-stimulating adjuvant is IL-15.
9. The pharmaceutical composition of claim 5 , wherein the immune-stimulating adjuvant is IL-21.
10. The pharmaceutical composition of claim 4 , further comprising pharmaceutically acceptable excipients.
11. The pharmaceutical composition of claim 10 , wherein said pharmaceutically acceptable excipients are selected from the group consisting of buffers, diluents, flavors, and lubricants.
12. The pharmaceutical composition of claim 4 , further comprising a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution, and dextrose solution.
14. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.
15. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.
16. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is trifluoro-acetate salt.
17. A fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii) and a peptide consisting of the amino acid sequence of SLLELDGINL (SEQ ID NO: 72).
18. A kit comprising: (a) a container comprising a pharmaceutical composition containing the peptide according to claim 1 ; (b) optionally, a second container containing a diluent or reconstituting solution for a lyophilized formulation; and (c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of a lyophilized formulation.